他汀类药物的使用已被证明与多种癌症的风险降低有关，但尚不能确定这种关联对于弥漫性大B细胞淋巴瘤（DLBCL）的影响。本研究旨在系统总结关于这种关联的所有可用数据，并对其进行荟萃分析。采用EMBASE和MEDLINE数据库，检索时间从首次记录至2019年10月，搜索策略包括“他汀类药物”和“DLBCL”等术语。纳入的研究应为病例对照或队列研究，报告他汀类药物使用与DLBCL风险的关联。提取并结合相对风险、比值比（OR）、危险率、风险比或标准化发病率以及标准误差，使用随机效应、通用逆方差法计算汇总效应估计值。共筛选了1139篇文章，其中6个研究符合纳入标准并纳入荟萃分析。他汀类药物使用与显著降低的DLBCL风险相关，汇总OR为0.70（95%置信区间为0.56-0.88；I[2]=70%）。漏斗图（相对对称）提示未发现出版偏倚的存在。本研究的系统综述和荟萃分析发现，他汀类药物使用与DLBCL的减少风险关联，几率减少了30%。然而，汇总分析使用了观察性研究的数据，因此无法得出因果关系的结论。因此，建议仍需要进行随机对照研究来确认这种潜在的益处。

Statin use has been shown to be associated with a decreased risk of several types of cancer, however, the data on diffuse large B-cell lymphoma (DLBCL) are still inconclusive. This study aimed to systematically summarize all available data on this association and conduct a meta-analysis on the same.A systematic review was performed using EMBASE and MEDLINE databases from inception upto October 2019 with a search strategy that included terms such as 'statin' and 'DLBCL'. Eligible studies included either case-control or cohort studies that reported the association between statin use and the risk of DLBCL. Relative risk, odds ratio (OR), hazard: risk ratio or standardized incidence ratio of this association and standard error were extracted and combined for calculating the pooled effect estimate using random-effects, generic inverse variance method.A total of 1139 articles were screened. Of these six studies satisfied the inclusion criteria and were included for the meta-analysis. Statin use was associated with a significantly reduced risk of DLBCL with the pooled OR of 0.70 (95% confidence interval, 0.56-0.88; I[2]=70%). The funnel plot (fairly symmetric) was not suggestive of the presence of a publication bias.The present systematic review and meta-analysis found that statin use is associated with a 30 per cent reduced odds of DLBCL. However, the pooled analysis utilized data from observational studies so causation cannot be concluded upon. Hence, it suggested that randomized-controlled studies are still needed to confirm this potential benefit.